尿路上皮性肿瘤组织中多药耐药基因及其相关蛋白的表达

Expression of MDR-1 and MRP of human urothelial tumor of urinary tract

[目的]观察尿路上皮性肿瘤组织中多药耐药基因(MDR1)和多药耐药基因相关蛋白(MRP)的表达情况.[方法]运用RTPCR技术,对75例施行内窥镜检查患者的尿路上皮性肿瘤组织中的MDR1和MRP进行测定.[结果]尿路上皮性肿瘤组织中MDR1的表达率为87%(65/75),其中肾盂癌为100%(11/11),输尿管癌为75%(15/20),膀胱癌为89%(39/44);MRP的阳性表达率为60%(45/75),其中肾盂癌为36%(4/11),输尿管癌为58%(11/19),膀胱癌为68%(30/44).膀胱内肿瘤的MDR1与MRP的表达趋势一致,表达率随发生部位的下移均逐渐升高.[结论]尿路上皮性肿瘤组织中MDR1具有高度表达性;MDR1及MRP表达与尿路上皮性肿瘤的发生部位无关;膀胱内不同部位肿瘤组织中MDR1的表达与肿瘤的发生部位无关.

OBJECTIVE?To investigate the expression of MDR-1 and MRP of human urothelial tumor of ~urinary tract.?METHODS?From 75 patients of human urothelial tumor of urinary tract, expression of MDR-1 and MRP in the sections by endoscopic biopsy were detected by RT-PCR.?RESULTS?Expression of the MDR-1 was 87% (65/75), including 100% (11/11) of renal pelvic carcinoma, 75% (15/20) of ureteral carcinoma and 89% (39/44) of bladder carcinoma. Expression of the MRP was 60% (45/75), including 36% (4/11) of renal pelvic carcinoma, 58% (11/19) of ureteral carcinoma and 68% (30/44) of bladder carcinoma. The positive expression of both MDR-1 and MRP was increasing along with moving down to the lower position of bladder tumors.?CONCLUSION?Expression of the MDR-1 gene is high in most unchemotherapeutic urothelial tumor of urinary tract and of the MRP is low. Expression of the MDR-1 and MRP There was a significant relationship between MRP positive specimens with the occurrence of cancer position in bladder and there was no significant relationship between MDR-1 positive specimens and the occurrence of cancer position.